LYEL   $20.77  3.54% Market Closed

Lyell Immunopharma, Inc.
Total Cash 491.12M
totalCashPerShare 1.918
EBITDA -204.47M
Total Debt 60.22M
quickRatio 15.905
currentRatio 16.187
Total Revenue 54.00K
debtToEquity 10.63
Revenue/Share 0.0
ROA -0.18845
ROE -0.32264
grossProfits
freeCashflow -87.02M
operatingCashflow -158.43M
earningsGrowth
revenueGrowth -0.519
grossMargins 1.0
ebitdaMargins 0.0
operatingMargins -3963.6921
profitMargins 0.0
enterpriseValue -52.01M
forwardPE -1.7619048
floatShares 166.70M
sharesOutstanding 256.59M
sharesShort 10.76M
sharesShortPriorMonth 13.22M
dateShortInterest
sharesPercentSharesOut 0.04%
heldPercentInsiders 0.13%
heldPercentInstitutions 0.59%
Short Ratio help_outline 13.91%
shortPercentOfFloat 0.06%
impliedSharesOutstanding
bookValue 2.213
Price To Book help_outline 0.67
earningsQuarterlyGrowth
netIncomeToCommon -210.26M
trailingEps -0.99%
forwardEps -0.84%
enterpriseToEbitda 0.25
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.2 3Q 2024
institutionsCount 167
lastUpdated Nov. 7, 2024, 5:08 a.m.